Claims for Patent: 6,881,727

Summary for Patent: 6,881,727

Title:	Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
Abstract:	Compounds having a metalloproteinase inhibitory activity, represented by the formula (I), its optically active isomers, their pharmaceutically acceptable salts, or hydrates thereof. ##STR1##
Inventor(s):	Watanabe; Fumihiko (Nara, JP), Tsuzuki; Hiroshige (Kyoto, JP), Ohtani; Mitsuaki (Nara, JP)
Assignee:	Shionogi & Co., Ltd. (Osaka, JP)
Application Number:	10/188,115
Patent Claims:	1. A composition for inhibiting metalloproteinase which comprises a compound of the formula I: ##STR628## wherein R.sup.1 is optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heteroaryl; R.sup.2 is a hydrogen atom, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; R.sup.3 is optionally substituted arylene; R.sup.4 is --CH.dbd.CH--, --C.ident.C--, --SO.sub.2 --NH--N.dbd.CH--, or tetrazol-diyl; R.sup.5 is optionally substituted aryl; and Y is --NHOH or --OH; provided R.sup.2 is a hydrogen atom when Y is --NHOH; or an optically active substance, a pharmaceutically acceptable salt, or hydrate thereof. 2. A composition for inhibiting metalloproteinase which comprises a compound of the formula I: ##STR629## wherein R.sup.1 is optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heteroaryl; R.sup.2 is a hydrogen atom, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; R.sup.3 is optionally substituted arylene; R.sup.4 is --CH.dbd.CH--, --C.ident.C--, --SO.sub.2 --NH--N.dbd.CH--, or tetrazol-diyl; R.sup.5 is optionally substituted aryl; and Y is --NHOH or --OH; provided R.sup.2 is a hydrogen atom when Y is --NHOH; or an optically active substance, a pharmaceutically acceptable salt, or hydrate thereof. 3. A compound of the formula I: ##STR630## wherein R.sup.1 is optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heteroaryl; R.sup.2 is a hydrogen atom, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; R.sup.3 is optionally substituted arylene; R.sup.4 --(CH.sub.2).sub.m --, --CH.dbd.CH--, --C.ident.C--, SO.sub.2 --NH--N.dbd.CH--, or tetrazol-diyl; R.sup.5 is optionally aryl; Y is --NHOH or --OH; and m is 1 or 2; provided R.sup.2 is hydrogen atom when Y is --NHOH, R.sup.4 is not --O-- when R.sup.3 is optionally substituted arylene, R.sup.3 is not 1,2-phenylene or an optically active substance, a pharmaceutically acceptable salt, or hydrate thereof. 4. A compound of the formula II: ##STR631## wherein R.sup.6 is --SO.sub.2 --NH--N.dbd.CH--; R.sup.7 is optionally substituted aryl; R.sup.8 and R.sup.9 are each independently hydrogen atom, lower alkoxy, or nitro; R.sup.1 is optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heteroaryl; R.sup.2 is hydrogen atom, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; Y is --NHOH or --OH; or an optically active substance, a pharmaceutically acceptable salt, or hydrate thereof. 5. A compound of the formula III: ##STR632## wherein R.sup.10 is tetrazol-diyl; R.sup.1 is optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heteroaryl; R.sup.2 is a hydrogen atom, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; R.sup.7 is optionally substituted aryl; R.sup.8 and R.sup.9 are each independently a hydrogen atom, lower alkoxy, or nitro; Y is --NHOH or --OH; or an optically active substance, a pharmaceutically acceptable salt, or hydrate thereof. 6. A compound of formula I': ##STR633## wherein R.sup.1' is benzyl, (indol-3-yl)methyl, (1-methylindol-3-yl)methyl, (5-methylindol-3-yl)methyl, (5-fluoroindol-3-yl)methyl, (1-acetylindol-3-yl)methyl, (1-methylsulfonylindol-3-yl)methyl, (1-alkoxycarbonyl-3-yl)methyl, (1-ethoxycarbonyl-3-yl)methyl or (1-isopropoxycarbonyl-3-yl)methyl; R.sup.2' is hydrogen atom, methyl, 4-aminobutyl, or benzyl; R.sup.3' is 1,4-phenylene; R.sup.4' is --O--; R.sup.5' is phenyl or 4-hydroxyphenyl; and Y is --NHOH or --OH, its optically active form, pharmaceutically acceptable salt, or hydrate thereof. 7. A compound of formula V: ##STR634## wherein R.sup.12 is --CH.dbd.CH-- or --C.ident.C--; R.sup.1 is optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heteroaryl; R.sup.2 is hydrogen atom, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; R.sup.7 is optionally substituted aryl; R.sup.8 and R.sup.9 are each independently hydrogen atom, lower alkoxy, or nitro; its optically active substance, pharmaceutically acceptable salt, or hydrate thereof. 8. A compound of formula VII: ##STR635## R.sup.1 is optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; R.sup.2 is hydrogen atom, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; R.sup.7 is optionally substituted aryl; R.sup.8 and R.sup.9 are each independently hydrogen atom, lower alkoxy, or nitro; its optically active form, pharmaceutically acceptable salt, or hydrate thereof. 9. A compound of formula X: ##STR636## wherein R.sup.12 is --CH.dbd.CH-- or --C.ident.C--; R.sup.1 is optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heteroaryl; R.sup.7 is optionally substituted aryl; R.sup.8 and R.sup.9 are each independently hydrogen atom, lower alkoxy, or nitro; its optically active form, pharmaceutically acceptable salt, or hydrate thereof. 10. A compound of formula XII: ##STR637## R.sup.1 is optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; R.sup.7 is optionally substituted aryl; R.sup.8 and R.sup.9 are each independently hydrogen atom, lower alkoxy, or nitro; its optically active form, pharmaceutically acceptable salt, or hydrate thereof. 11. The compound of claim 3, wherein R.sup.1 is isopropyl or benzyl. 12. The compound of claim 3, wherein R.sup.5 is phenyl optionally substituted with one or more substituents selected from the group consisting of alkoxy, alkylthio, and alkyl. 13. The compound of claim 3, wherein a configuration of asymmetric carbon atoms bonding with R.sup.1 is R configuration. 14. A pharmaceutical composition comprising a compound of claim 3. 15. A pharmaceutical composition comprising a compound of claim 11. 16. A pharmaceutical composition comprising a compound of claim 12. 17. A pharmaceutical composition comprising a compound of claim 13. 18. A method of inhibiting the activity of a metalloproteinase to treat a disease selected from the group consisting of osteoarthritis, rheumatoid arthritis, corneal ulceration, periodontal disease, metastasis and invasion of tumor, advanced virus infection, arteriosclerosis obliterans, arteriosclerotic aneurysm, atherosclerosis, restenosis, sepsis, septic shock, coronary thrombosis, aberrant angiogenesis, scleritis, multiple sclerosis, open angle glaucoma, retinopathies, proliferative retinopathy, neovascular glaucoma, pterygium, keratitis, epidermolysis bullosa, psoriasis, diabetes, nephritis, gingivitis, tumor growth, tumor angiogenesis, ocular tumor, angiofibroma, hemangioma, fever, hemorrhage, coagulation, cachexia, anorexia, acute infection, shock, malaria, Crohn's disease, meningitis, and gastric ulcer, comprising administering to a subject in need of an effective amount of a compound of formula I: ##STR638## wherein R.sup.1 is optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heteroaryl; R.sup.2 is a hydrogen atom, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; R.sup.3 is a bond or optionally substituted arylene; R.sup.4 is --(CH.sub.2).sub.m --, --CH.dbd.CH--, --C.ident.C--, --N.dbd.N--, --N(R.sup.A), --O--, --S--, --SO.sub.2 NH--, --SO.sub.2 --NH--N.dbd.CH--, or tetrazol-diyl; R.sup.5 is optionally substituted aryl; R.sup.A is hydrogen atom or lower alkyl; Y is --NHOH or --OH; and m is 1 or 2; provided R.sup.2 is hydrogen atom when Y is --NHOH, or an optically active substance, a pharmaceutically acceptable salt, or hydrate thereof. 19. A method of inhibiting the activity of a type-IV collagenase, to treat a disease selected from the group consisting of osteoarthritis, rheumatoid arthritis, corneal ulceration, periodontal disease, metastasis and invasion of tumor, advanced virus infection, arteriosclerosis obliterans, arteriosclerotic aneurysm, atherosclerosis, restenosis, sepsis, septic shock, coronary thrombosis, aberrant angiogenesis, scleritis, multiple sclerosis, open angle glaucoma, retinopathies, proliferative retinopathy, neovascular glaucoma, pterygium, keratitis, epidermolysis bullosa, psoriasis, diabetes, nephritis, gingivitis, tumor growth, tumor angiogenesis, ocular tumor, angiofibroma, hemangioma, fever, hemorrhage, coagulation, cachexia, anorexia, acute infection, shock, malaria, Crohn's disease, meningitis, and gastric ulcer, comprising administering to a subject in need of an effective amount of a compound of formula I: ##STR639## wherein R.sup.1 is optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heteroaryl; R.sup.2 is a hydrogen atom, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; R.sup.3 is a bond or optionally substituted arylene; R.sup.4 is --(CH.sub.2).sub.m --, --CH.dbd.CH--, --C.ident.C--, ----N.dbd.N--, --N(R.sup.A)--, --O--, --S--, --SO.sub.2 NH--, --SO.sub.2 --NH--N.dbd.CH--, or tetrazol-diyl; R.sup.5 is optionally substituted lower alkyl, optionally substituted C.sub.3 -C.sub.8 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or an optionally substituted non-aromatic heterocyclic group; R.sup.A is hydrogen atom or lower alkyl; Y is --NHOH or --OH; and m is 1 or 2; provided R.sup.2 is hydrogen atom when Y is --NHOH, or an optically active substance, a pharmaceutically acceptable salt, or hydrate thereof. 20. The compound of claim 6, wherein R.sup.1' is isopropyl or benzyl. 21. The compound of claim 4, wherein R.sup.7 is phenyl optionally substituted with one or more substituents selected from the group consisting of alkoxy, alkylthio, and alkyl. 22. The compound of claim 6, wherein a configuration of asymmetric carbon atoms bonding with R.sup.1' is R configuration. 23. The compound according to claim 3, wherein R.sup.4 is --(CH.sub.2).sub.m --, --CH.dbd.CH--, or --C.ident.C--; and m is 1 or 2, its optically active form, a pharmaceutically acceptable salt thereof, or a hydrate thereof. 24. The compound according to claim 3, wherein R.sup.1 is optionally substituted lower alkyl; R.sup.2 is hydrogen or optionally substituted lower alkyl; R.sup.3 is optionally substituted arylene; R.sup.4 is --(CH.sub.2).sub.m --, --CH.dbd.CH--, --C.ident.C--; R.sup.5 is optionally substituted aryl or optionally substituted heteroaryl; and m is 1 or 2, its optically active form, a pharmaceutically acceptable salt thereof, or a hydrate thereof. 25. A compound of the formula: ##STR640## wherein R.sup.12 is --CH.dbd.CH--, --C.ident.C--, --O-- or ##STR641## R.sup.1 is optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heteroaryl; R.sup.2 is hydrogen atom, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; R.sup.7 is optionally substituted aryl or optionally substituted heteroaryl; R.sup.8 and R.sup.9 are each independently hydrogen atom, lower alkoxy, or nitro; its optically active form, pharmaceutically acceptable salt, or hydrate thereof.

Details for Patent 6,881,727

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2016-01-23